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Abstract
Introduction: Despite the broad spectrum of antirheumatic drugs, RA is still not well controlled in up to 30-50 % of
patients. Inhibition of JAK kinases by means of the pan-JAK inhibitor tofacitinib has demonstrated to be effective even
in difficult-to-treat patients. Here, we discuss whether the efficacy of JAK inhibition can be improved by simultaneously
inhibiting SYK kinase, since both kinases mediate complementary and non-redundant pathways in RA.
Methods: Efficacy of dual JAK + SYK inhibition with selective small molecule inhibitors was evaluated in chronic
G6PI-induced arthritis, a non-self-remitting and destructive arthritis model in mice. Clinical and histopathological
scores, as well as cytokine and anti-G6PI antibody production were assessed in both preventive and curative
protocols. Potential immunotoxicity was also evaluated in G6PI-induced arthritis and in a 28-day TDAR model, by
analysing the effects of JAK + SYK inhibition on hematological parameters, lymphoid organs, leukocyte subsets
and cell function.
Results: Simultaneous JAK + SYK inhibition completely prevented mice from developing arthritis. This therapeutic
strategy was also very effective in ameliorating already established arthritis. Dual kinase inhibition immediately
resulted in greatly decreased clinical and histopathological scores and led to disease remission in over 70 % of the
animals. In contrast, single JAK inhibition and anti-TNF therapy (etanercept) were able to stop disease progression but
not to revert it. Dual kinase inhibition decreased Treg and NK cell counts to the same extent as single JAK inhibition
but overall cytotoxicity remained intact. Interestingly, treatment discontinuation rapidly reversed such immune
cell reduction without compromising clinical efficacy, suggesting long-lasting curative effects. Dual kinase inhibition
reduced the Th1/Th17 cytokine cascade and the differentiation and function of joint cells, in particular osteoclasts and
fibroblast-like synoviocytes.
Conclusions: Concurrent JAK + SYK inhibition resulted in higher efficacy than single kinase inhibition and TNF blockade
in a chronic and severe arthritis model. Thus, blockade of multiple immune signals with dual JAK + SYK inhibition
represents a reasonable therapeutic strategy for RA, in particular in patients with inadequate responses to current
treatments. Our data supports the multiplicity of events underlying this heterogeneous and complex disease.
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Introduction
Many patients with rheumatoid arthritis (RA) continue
with persistently active disease. The conventional
disease-modifying anti-rheumatic drugs (DMARDs),
most commonly methotrexate (MTX), non-steroidal
anti-inflammatory drugs (NSAIDs) and steroids, can
inhibit local inflammatory symptoms but have little or
insufficient long-lasting systemic effects. This prompted
the emergence of biologic agents targeting specific inter-
cellular signals, such as antagonists of TNF, IL-6 and
IL-1β, which apart from their anti-inflammatory effects
directly reduce the pathogenic activity of synovial cells.
Biologic agents targeting specific immune cells, such as
modulators of B cell and T cell activity, were approved for
RA patients not responding adequately to oral DMARDs
or other biologic agents. While biologic agents have
greatly improved the effectiveness of RA treatment,
30–40 % of patients still do not have an appropriate re-
sponse and, therefore, have interruptions in treatment [1].
Indeed, their required chronic use increases the risk of
developing cancer and infection, and can cause drug
resistance. In addition, biologic agents are expensive, have
long half-lives and must be injected or infused, which
highlights the need for better therapies.
Small molecule drugs, such as inhibitors of protein
kinases, appear to be a good alternative due to their
ability to immunomodulate multiple key intracellular sig-
nals. Furthermore, these chemical compounds (<1 kDa)
are orally available and have a short half-life, which facili-
tates treatment modulation. Persuasive preclinical data
support the targeting of specific members of the mitogen-
activated protein kinase (MAPK) (e.g., p38-α) and PI3K/
Akt/mTOR (p110δ) pathways but none of the inhibitors
have progressed to phase III clinical studies due to lack of
efficacy in RA patients and concerns about toxicity
(reviewed in [2, 3]). The focus is now placed on kinases
higher in the signaling cascade, such as the non-receptor
cytoplasmic tyrosine kinases Janus kinase (JAK) and the
spleen tyrosine kinase (SYK).
The JAK family in mammals includes the closely
related isoforms JAK1, JAK2, JAK3 and TYK2 (tyrosine
kinase 2), which homo/heterodimerize and bind to
cytokine receptors. The JAK/STAT signaling pathways
mediate the effects of many cytokines/interferons and
growth factors important in RA (e.g., IL-2, IL-6, IL-7, IL-
10, IL-12, IL-15, IL-21, IL-23, interferons (IFNs), granulo-
cyte macrophage colony-stimulating factor (GM-CSF))
and regulate the activity of hemopoietic and joint resident
cells. In fact, the relevance of some of these signals has
been validated in the clinics through their blockade using
specific biologic drugs [4, 5]. It is, thus, not surprising that
JAK inhibitors have proved efficacious in animal models
of arthritis [6, 7], and in clinics [8, 9]. Indeed, the small
pan-JAK inhibitor tofacitinib (CP-690,550) was approved
for the treatment of moderate to severe RA in patients
who do not respond to MTX or conventional synthetic
and biological DMARDs [10, 11]. JAK inhibition has
demonstrated high efficacy, as approximately 60–70 % RA
patients experience clinical improvement with at least 20 %
response according to American College of Rheumatology
criteria (ACR20 response) [12], even in non-responders to
anti-TNF treatment (ACR20 of 48 %) [13]. As such, Lee et
al. recently suggested that tofacitinib could be used as first-
line monotherapy for RA [14].
SYK kinase is required for the signal transduction of
receptors that associate with transmembrane proteins
containing immunoreceptor tyrosine activation motifs
(ITAM), i.e., the B cell receptor, T cell receptor and
certain Fc receptors primarily present in granulocytes,
dendritic cells (DCs) and macrophages. SYK additionally
mediates signaling by integrins and members of the
lectin/selectin families [15] and is involved in the activity
of non-immune cells, such as fibroblast-like synoviocytes
(FLS) and vascular endothelial cells [16–18]. As SYK is
implicated in several pathways linked to RA pathogen-
esis, SYK inhibition is viewed as a plausible therapeutic
strategy. To our knowledge, selective SYK inhibitors,
such as PRT062607 (Portola/Biogen Idec), have shown
encouraging preclinical data [19] but their potential
efficacy in RA patients has not been evaluated. Here, we
investigated whether the high efficacy of JAK inhibition
could be improved by concurrently inhibiting SYK. To
this end, we used potent and selective small molecule in-
hibitors of pan-JAKs (tofacitinib) and SYK (PRT062607)
either in combination or alone, which were tested, for
the first time, in a destructive and non-remitting arthritis
murine model [20, 21].
Methods
Induction and scoring of arthritis
DBA/1 mice (six w.o. males from Janvier, France) were
immunized subcutaneously (s.c.) (100 μl at each side of
the base of the tail) with 400 μg recombinant human (rhu)
glucose-6-phosphate isomerase (G6PI) emulsified in
complete Freund’s adjuvant (CFA, Sigma-Aldrich, St.
Louis, MO, USA) on day 0, as previously described [20].
The indicated amount of antigen was mixed with CFA in
a 1:1 ratio (v/v) and emulsified with a Polytron. When spe-
cified, regulatory T cells (Tregs) were depleted injecting
intraperitoneally (i.p.) 400 μg anti-CD25 Ab (PC61.5,
BioXcell, West Lebanon, NH, USA) 11 and 8 days before
immunization [21].
The mouse weight was recorded and the clinical score
was evaluated over time. Each paw section was scored sep-
arately, and these scores were all added together as follows:
Total score per mouse = (Sum of scores of 2 wrists + 2
ankles (i.e., max 12)) + (Sum of scores of 2 metacarpals
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+ 2 feet (i.e., max 12)) + (Number of inflamed fingers
(max 8) + toes (max 10)/2 (i.e., max score of 9)).
For each paw section, a score of 0 to 3 was assigned,
where 0 indicates no clinical signs of arthritis (healthy
state), 1 and 2 indicate mild/intermediate swelling and
redness of the paw, and 3 indicates massive swelling,
redness and burst skin.
All experiments with mice were approved by the
Animal Experimentation Ethical Committee of Draconis
Pharma, the Animal Experimentation Commission of
the Generalitat de Catalunya (Catalonian Government)
or the German federal state institution Landesamt für
Gesundheit und Soziales.
T cell-dependent antibody response (TDAR) model
CD-1 mice (six to eight w.o. females from Janvier,
France) were immunized on day 0 with 300 μg of key-
hole limpet hemocyanin (KLH, Sigma-Aldrich, subplan-
tar injection of 30 μl). On day 14, mice were sacrificed
and blood, plasma and spleens were obtained.
Treatments
The kinase inhibitors Tofacitinib (JAKi) and PRT-062607
(SYKi) were synthesized by Aptonchem Co.
Ltd. (Hangzhou, China) or in house (Draconis Pharma),
respectively. These compounds were diluted in water, son-
icated for 5 minutes and given orally (p.o.) (20 mg/kg JAKi
and 30 mg/kg SYKi) once daily (QD) starting on day 0 or
12, unless otherwise specified. We corrected the amount
of each compound used by the molecular weight (MW) of
the free amine: MW of JAKi = 504.49 g/mol (free amine
312.37 g/mol) and MW of SYKi = 453.50 g/mol (free
amine 393.45 g/mol). Prednisolone (Sigma-Aldrich,
3 mg/kg) was also diluted in water and given p.o.
QD. The soluble dimeric human TNFR p75–IgG-Fc
fusion protein (etanercept, Enbrel®, Pfizer, Thousand
Oaks, CA, USA) was diluted in PBS and given s.c.
(10 mg/kg) every third day.
Sample collection
Samples were obtained at the indicated time points.
Inguinal lymph nodes and spleens were weighted and
single cell suspensions were made in Roswell Park Me-
morial Institute (RPMI)1640 medium (Life technologies,
ThermoFisher Scientific, Eugene, OR, USA, supple-
mented with 10 % FBS, glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin) by mechanical disruption of
the tissue with a syringe plunger on a 40-μm cell
strainer. Peripheral blood was collected in tubes with
0.5 % K2-EDTA, hematological parameters analyzed by
Celltac E analyzer (Nihon Khoden, Tokyo, Japan) and
plasma stored at −80 °C for cytokine and Ig quantifica-
tion. Ankle swelling was measured using a dial-gauge
caliper (Peacok, Ozaki MFG Co. Ltd., Tokyo, Japan); the
average thickness of both hind legs was used. The right
hind limb of each mouse was fixed in 10 % formalin and
then decalcified with Osteomoll (Merck Millipore) for
histopathological assessment.
Cytokine production by splenocytes
Splenocytes were plated in triplicates (8 × 105 cells/well in
96-well flat-bottom plates) and re-stimulated with either
20 μg/ml rhu G6PI or PBS in RPMI medium supple-
mented with 10 % FBS, 100 U/ml penicillin and 100 μg/
ml streptomycin at 37 °C in 5 % CO2 for 72 h. When indi-
cated, splenocytes from non-treated arthritic mice were
also exposed to 0.5 μM of JAKi and 0.5 μM of SYKi for
72 h. Supernatants were collected and murine IFNγ, IL-
17A and IL-6 were measured by ELISA (BD, Franklin
Lakes, NJ, USA, and Affymetrix, Santa Clara, CA, USA
and eBioscience, San Diego, CA, USA), according to man-
ufacturer’s protocols.
G6PI- and KLH-specific Ig ELISA
Plasma levels of G6PI- and KLH-specific antibodies were
measured by ELISA. Briefly, 96-well flat-bottom plates
were coated with 5 μg/ml of G6PI or 10 μg/ml of KLH
in carbonate buffer (0.1 M Na2CO3 and NaHCO3,
pH 9.5) overnight at 4 °C, washed with PBS containing
0.05 % Tween-20 (Sigma-Aldrich) and incubated with a
blocking buffer (2 % BSA (Sigma-Aldrich) in PBS) for
1 h to saturate non-specific binding sites. Serial 5-fold or
10-fold dilutions of the plasma in PBS + 0.05 % Tween +
2 % BSA were added for 2 h followed by 1 h incubation
with isotype-specific Ab with peroxidase (goat anti-
mouse Fcγ- or Fcμ-specific Ab-HRP, Jackson ImmunoR-
esearch, Suffolk, UK). After washing, the substrate 3,3′-
5,5′ tetramethylbenzidin (TMB) (BD) was added, the re-
action was stopped with 1 M H2SO4 and the absorbance
was determined at 450 nm with a reference wavelength
of 570 nm.
Immunophenotyping by flow cytometry
Cell surface phenotyping was performed by using anti-
mouse antibodies to CD3, CD4, CD8, CD19, CD11c,
CD11b, MHCII, CD86, CD49b, CD25, CD44, CD138 and/
or fixable live/dead. For intracellular markers, cells were
fixed, permeabilized and stained with anti-Foxp3, CD40L,
IFNγ, IL-2, TNFα, 5-Bromo-2′-deoxyuridine (BrdU),
ovalbumin (OVA), κ and/or λ. Cells were analyzed with
a FACS Calibur or a LSR Fortessa flow cytometer (BD
Biosciences) and data were analyzed using FlowJo software.
Cell-mediated cytotoxicity (CDC) assay
Murine splenocytes (effector cells, EC) were isolated
from treated and untreated mice. Target cells (TC,
YAC-1 cell line) were labeled with 2.5 μM CFSE
fluorescent dye (Life technologies) to separate them
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from the EC population. Untreated splenocytes were
treated in vitro for 1 h at 37 °C with JAKi + SYKi or
anti-TNF, as indicated. Then, labeled TC were co-
incubated with EC (ratio of 1 TC:10 EC) for 4 h and
the dye PI (Life technologies) was added to discrimin-
ate live and dead cells.
Phagocytosis assay
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from human buffy coats by Ficoll density gradient.
Cells (2 × 106 cells/tube) were pre-treated with JAKi
and/or SYKi for 1 h. Media were removed and replaced
with 1 mg/ml Red pHrodoTM BioParticles® suspension
(Life Technologies) and incubated for 1.5 h at 37 °C. Phago-
cytosis of particles was quantified by flow cytometry.
Gene expression
Total RNA was purified from splenocytes using the Pure-
Link RNA Mini kit (Ambion, ThermoFisher Scientific,
Carlsbad, CA, USA) and the concentration and purity were
assessed using a Safire spectrophotometer (Tecan, Männe-
dorf, Switzerland). RNA (1 μg) was retro-transcribed to
cDNA using High-Capacity cDNA Reverse Transcription
kit (Life technologies) following manufacturer’s instruc-
tions. RANKL, IFNγ and IL-6 expression were evaluated
by quantitative real-time PCR using TaqMan Universal
Master Mix and a 7500 Real Time PCR System (Applied
Biosystems, ThermoFisher Scientific). Relative quantifica-
tion was determined using the comparative method: 18S
ribosomal RNA was used as the housekeeping gene
(Mm04277571_s1). Taqman probes for RANKL, IFNγ and
IL6 were Mm00441906_m1, Mm00801778_m1 and
Mm00446190_m1, respectively (Applied Biosystems).
Histopathological assessment
Tissue samples were paraffin-embedded and longitudinal
microsections were stained with H&E (Merck Millipore),
according to standard procedures. A score of 0 (normal)
to 5 (strongly affected) was given based on the degree of
inflammation, bone erosion, cartilage damage and pan-
nus formation in tarsus and phalanges, as previously
described [22, 23]. Experienced pathologists at AnaPath
(Spain) processed the tissues and performed the blinded
histopathological assessment.
Fibroblast-like synoviocyte (FLS) isolation, stimulation and
invasion assay
Small joints from Treg-depleted mice at day 56 post-
immunization were dissected and digested in 1 mg/ml
collagenase type IV solution for 2 h (Worthington
Biochemical Corp., Lakewood, NJ, USA 250 U/mg). FLS
were cultured in DMEM (Sigma-Aldrich) supplemented
with 10 % FBS, 100 U/ml Penicillin/Streptomycin (Jena
Bioscience, Jena, Germany) and 10 mM Hepes (Serva,
Heidelberg, Germany). All the FLS used were between
passages 4 and 5. FLS were plated (5 × 104 cells/well in
24-well plates) and stimulated with 10 ng/ml rmTNF-α
and 50 ng/ml of rmIL-17A (both Peprotech, London,
UK) or left unstimulated. All cells were also treated with
0.5 μM JAKi and/or SYKi; dimethyl sulfoxide (DMSO)
only was used as a control. After 24 h of incubation, the
supernatants were harvested and IL-6, matrix
metalloproteinase-3 (MMP-3) and MMP-9 were quanti-
fied by ELISA (reagents from eBioscience, San Diego, CA,
USA and Peprotech for IL-6; commercial DuoSet kits
from R&D Systems, Minneapolis, MN, USA for MMPs).
To test FLS invasiveness, a transwell system was used.
ThinCerts™ inserts with 8-μm pores (Greiner bio-one,
Frickenhausen, Germany) were coated with a bovine col-
lagen solution (PureCol ®, Advanced BioMatrix, Carls-
bad, CA, USA; 10 ×MEM, Gibco, ThermoFisher
Scientific, Waltham, MA, USA; sodium bicarbonate
7.5 %, Gibco) and put in 24-well plates. FLS (2 × 104
cells/well) resuspended in culture medium without
FBS in the presence of 0.5 μM of JAKi and/or SYKi
or DMSO only, were seeded on top of the collagen
matrix. Culture medium with 10 % FBS was used as
chemoattractant. After 48 h of incubation, the cells
that did not migrate were removed from the upper
part of the insert with a cotton swab and the lower
part of the insert was stained with crystal violet. The
percentage of invaded area was calculated using the
program Fiji, as described [24].
Osteoclast differentiation and bone resorption assay
Bone marrow cells were collected after flushing out of
femurs and tibiae, subjected to gradient purification
using ficoll-paque (GE Healthcare, Little Chalfont, Buck-
inghamshire, UK), plated in 96-well plates at a density of
6 × 104 cells/well and cultured in αMEM medium
(Gibco) containing 10 % FBS supplemented with 40 ng/
ml rank ligand (RANKL) (R&D Systems) and 25 ng/
ml M-CSF (R&D Systems) [25] in the presence or ab-
sence of CP and PRT compounds for 5 days. To visualize
osteoclasts, cell cultures were stained with tartrate-
resistant acid phosphatase (TRAP), using an acid phos-
phatase leukocyte (TRAP) kit (Sigma-Aldrich).
To assess osteoclast activity, bone marrow cells were
seeded on 650-μm-thick bovine cortical bone slices
(105 cells/slice) in αMEM supplemented with 5 %
FBS, 20 ng/ml RANK-L and M-CSF (30 ng/ml).
Medium was refreshed after 3 days. Differentiated
osteoclasts were treated with DMSO or 0.5 μM of
JAKi and/or SYKi on day 5 and bone resorption was
assessed 48 h later. Osteoclasts were lysed with water
and mechanically removed by sonicating the bone slices in
10 % NH3 for 20 minutes. Finally, bone slices were
washed, incubated for 10 minutes with 10 % hydrated
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potassium aluminium sulfate, washed again and stained
with Coomassie blue (PhastGel Blue R-350; GE Health-
care Bioscience, Uppsale, Sweden) in order to visualize the
pits of resorption. Five micrographs per slice were acquired
with a digital camera mounted on an inverted light micro-
scope and the percentage of eroded area was quantified
using the program Leica Application Suite (version 4.3.0).
Memory cell
BALB/c mice (Charles River, Germany) were immunized
i.p. with 100 μg OVA (Sigma-Aldrich) in 100 μl alum
(ThermoFisher Scientific) at day 0. On day 21, mice
were boosted with 100 μg OVA in 100 μl alum. From
day 20 to 35, mice received 1 mg/ml BrdU (Sigma-Al-
drich) dissolved in drinking water to label newly gener-
ated plasma cells (i.e., plasma cells generated after
boost). From day 35 to 46, mice were treated with
20 mg/kg CP and/or 30 mg/kg PRT (p.o. QD). On day
46, single cell suspensions were generated from spleen
and bone marrow and stained for flow cytometry. For the
ex vivo re-stimulation assay, cells were plated in complete
RPMI medium in 12-well plates (107 cells/well) and re-
stimulated for 6 h with 100 μg OVA. Brefeldin A (BioLe-
gend, London, UK) was added after the first 4 h and finally
stained for flow cytometry.
Statistical analysis
Data are expressed as mean ± standard error of the mean
and were analyzed and graphed with Prism software ver-
sion 5 (GraphPad, La Jolla, CA, USA). Statistical analysis
was calculated using Student’s t test (unpaired, two-
tailed) and one-way or two-way analysis of variance
(with the Dunnett or Bonferroni post hoc test). Differ-
ences were considered statistically significant when the p
value was <0.05.
Results
Dose selection of potent and selective small JAK and SYK
inhibitors
We used tofacitinib (CP-690,550, designed by Pfizer) as
a selective pan-JAK inhibitor (JAKi) and PRT062607
(Portola Pharmaceuticals Inc. and Biogen Idec Inc.) to
specifically inhibit SYK (SYKi), or their combination
(JAKi + SYKi). In Additional file 1, we show data ob-
tained to determine the doses of inhibitors to be further
used for in vivo studies. Briefly, we first confirmed the
potency and selectivity of these inhibitors in biochemical
and cellular assays (half maximal inhibitory concentra-
tion (IC50) (JAK) approximately 0.02 μM and IC50 (SYK)
approximately 0.5 μM). We also determined their effi-
cacy in standard acute arthritis models in mice; namely
the collagen-induced arthritis (CIA) model, which
strongly relies on T cell function and therefore eases the
study of JAK inhibition (ED50 (JAK) approximately
11 mg/kg QD), and the collagen antibody-induced
arthritis (CAIA) model for SYK inhibition, as it requires
processing of anti-type II collagen antibodies and im-
mune complexes via FcR. Based on these results, we
decided to use a dosage of 20 mg/kg of tofacitinib (JAKi)
and 30 mg/kg of PRT062607 (SYKi) QD. A single oral
dose of tofacitinib or PRT062607 in naive mice resulted
in a rapid increase of plasma levels (tmax = 1–3 h), reach-
ing maximal concentrations that did not compromise
kinase selectivity, and were completely cleared daily.
Therefore, the selected doses guaranteed high efficacy
while maintaining selectivity.
Dual JAK + SYK inhibition prevents G6PI-induced arthritis
To test the efficacy of dual JAK + SYK inhibition, we chose
a novel and well-accepted murine model of arthritis
induced by the systemic antigen G6PI. Immunization is
achieved by administering G6PI along with CFA subcuta-
neously. The resulting acute, self-limited type of arthritis
[20] can be switched deliberately to a non-self-remitting
and destructive type by transiently depleting Treg cells
prior to disease induction [21]. This chronic model is
characterized by exacerbated clinical signs of inflamma-
tion (redness and paw swelling), joint deformations and
higher levels of T helper (Th1) and Th17 cytokines com-
pared to the acute type (see [21] and Additional file 2).
Here, we were interested in mimicking severe and non-
self-remitting disease, as it better represents human
disease; therefore, we used the chronic G6PI model.
In order to study the impact of kinase inhibition on
arthritis development, daily oral treatment with JAKi
and/or SYKi was started upon immunization (see a dia-
gram of this experimental protocol in Additional file 2).
Figure 1a shows that mice receiving SYKi developed
moderate and persistent arthritis compared to vehicle
controls and ended with 40 % lower clinical scores. Mice
treated with JAKi had mild inflammation of the paws,
except for the toes and fingers, for a week only, as clin-
ical signs were resolved in all mice after 17 days of treat-
ment. As a measure for the aggregate effect of these
treatments over time, the average area under the clinical
score curve decreased by 94 % with JAKi, but by only
33 % with SYKi. The greatest effects were observed with
the dual inhibition of JAK + SYK, which prevented all
mice from developing arthritis. None of the mice had in-
flammation of the toes/fingers and only 30 % were
scored with incipient swelling of the wrists/ankles for at
most 4 days. Accordingly, lymph node weights were
significantly decreased compared to the progressively
bigger ones in arthritic controls over time (Fig. 1b). In
the spleen, the CD11chi MHCII+ dendritic cell pool (not
shown), and consequently the number of activated
(CD86+) DCs (Fig. 1c), were reduced in mice treated
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with JAKi + SYKi, likely contributing to minimize antigen-
specific immune responses.
Parameters of T and B cell activity support a critical role
for JAK signaling in the induction phase of the disease.
Splenocytes from treated mice were stimulated in vitro
with G6PI for 72 h and cytokine production was quanti-
fied by ELISA. Levels of IFNγ, IL-17A and IL-6 were com-
parable in vehicle controls and SYKi-treated mice (Fig. 1d
Fig. 1 Efficacy of Janus kinase (JAK) + spleen tyrosine kinase (SYK) inhibition as a preventive treatment in glucose-6-phosphate isomerase (G6PI)-induced
arthritis. DBA/1 mice were immunized with G6PI + complete Freund’s adjuvant on day 0, after T regulatory cell depletion with anti-CD25 Ab
(days −8 and −11). Treatments (20 mg/kg of tofacitinib - JAK inhibitor (JAKi) - and/or 30 mg/kg of PRT062607 – SYK inhibitor (SYKi)) were orally
administered daily from day 0. Samples were obtained on day 31 unless otherwise specified. a Time course for arthritis scores and resulting
areas under these score curves. b Mean weight of both inguinal lymph nodes at day 6 and day 31 post-immunization. c Numbers of CD11chiMHCII+CD86
+ activated dendritic cells (DCs) in the spleen. d Cytokine secretion by splenocytes stimulated in vitro with 20 μg/ml recomninant human G6PI for 72 h. e
Numbers of CD19+MHCII+CD86+ activated B cells in the spleen. f Levels of G6PI-specific IgGs in plasma. g Histological features of G6PI-induced arthritis,
including severe inflammation and bone/cartilage destruction of tarsal and phalangeal joints from hind paws (H&E staining). Arrows cell aggregates (left,
bar 500 μM), infiltration of lymphocytes, macrophages and neutrophils in the synovium (middle, bar 200 μM) and osteoclasts (right, bar 50 μM). h and i Data
and representative histological sections of tarsal joints (bar 500 μM). Graphs show mean (+ standard error of the mean) for 3–5 mice/group, *p <0.05 versus
vehicle control, #p <0.05 versus non-immunized and untreated group (naive). N naive, V/Veh vehicle, IFN interferon
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and not shown). In contrast, JAKi decreased cytokine pro-
duction and a greater reduction was observed upon dual
JAKi + SYKi, confirming milder Th1/Th17 responses in
these groups. Similarly, CD86+-activated B cells and levels
of G6PI-specific IgGs were significantly lower in mice re-
ceiving JAKi or JAKi + SYKi (Fig. 1e and f).
A detailed histopathological evaluation of the hind limbs
of arthritic mice revealed severe lesions in both tarsal
(Fig. 1g-i) and phalangeal (not shown) joints with abun-
dant immune and inflammatory cells (primarily lympho-
cytes, macrophages and neutrophils), pannus formation
with neovascularization, marked cartilage and bone ero-
sion, loss of trabeculae and presence of more fibroblasts
and osteoclasts. Dual JAK + SYK inhibition prevented paw
inflammation and bone/cartilage damage. Most of these
effects were driven by JAK inhibition, which completely
cleared an initial mild inflammatory response and
prevented bone and cartilage erosion. With SYKi the
histopathology score was reduced by 30-40 % at day 31.
Dual JAK + SYK inhibition ameliorates chronic and severe
G6PI-induced arthritis
We next evaluated the therapeutic potential of dual JAK
+ SYK inhibition in a curative protocol, which is a more
strenuous measure of activity and is clinically more
relevant. In this case, oral daily treatment was started at
day 12 post-immunization, when clinical signs, primarily
inflammation in proximal and distal joints of paws, were
present. The clinical score of vehicle control mice
progressively increased, becoming stable around day 20
(Fig. 2a). Inhibition of JAK, but not SYK, was able to stop
disease progression, and after 2 weeks of treatment started
to mildly reduce arthritis severity. By day 31, mice treated
with JAKi or prednisolone (3 mg/kg QD), a corticosteroid
Fig. 2 Efficacy of Janus kinase (JAK) + spleen tyrosine kinase (SYK) inhibition as a curative treatment in glucose-6-phosphate isomerase (G6PI)-induced
arthritis. DBA/1 mice were immunized with G6PI + complete Freund’s adjuvant on day 0, after T regulatory cell depletion with anti-CD25 Ab (days −8
and −11). Treatments were orally administered daily from day 12 (red dotted line). Samples were obtained on day 31. a Time course for arthritis scores
and resulting areas under these score curves (AUC). b Detailed clinical score by paw segment at day 31. c Cytokine secretion by splenocytes stimulated
in vitro with 20 μg/ml recombinant human G6PI for 72 h. d Cytokine expression in splenocytes. e Numbers of CD19+MHCII+CD86+ activated B cells in
spleens. f Levels of G6PI-specific IgGs in plasma. g and h Data and representative histological sections of tarsal joints (bar 200 μM). Graphs show mean
(+ standard error of the mean) for 3–7 mice/group, *p <0.05 versus vehicle control. N naive, V/Veh vehicle, Pred/Predni prednisolone
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widely used as anti-inflammatory agent, had a reduction
in overall clinical score of 58 % and 74 %, respectively. In
contrast, dual JAKi + SYKi immediately prompted a grad-
ual decrease in the clinical score for all joints (Fig. 2b)
from all mice and over 70 % of these mice were totally
cured (score of 0) after 3 weeks of treatment.
Upon in vitro G6PI stimulation of splenocytes from
these mice, IL-6 production was only significantly reduced
in the dual treatment group (Fig. 2c), confirming attenu-
ation on antigen-specific responses. Th1 (IFNγ) and Th17
(IL-17A and IL-6) cytokine expression was also decreased
(Fig. 2d and not shown). Furthermore, combined JAKi +
SYKi was more effective at limiting B cell activation and
function, as assessed by the levels of serum G6PI-specific
IgG, relative to either inhibitor alone (Fig. 2e and f).
In terms of histopathological changes in tarsal
joints (Fig. 2g and h), single JAKi or SYKi decreased
around 50 % of joint inflammation, while dual treat-
ment induced a reduction of over 90 %. Of interest,
only simultaneous inhibition of JAK + SYK was able
to prevent bone and cartilage damage, showing a
completely normal joint structure in 60 % of mice.
Therefore, concurrent JAK + SYK inhibition amelio-
rates clinical, immunological and histological parame-
ters of arthritis.
Dual JAK + SYK inhibition is more effective than anti-TNF
treatment
We have showed greater efficacy of dual versus single
JAK and SYK inhibition in a chronic model of arthritis.
Fig. 3 Therapeutic comparison of Janus kinase (JAK) + spleen tyrosine kinase (SYK) inhibition and anti-TNF therapy in glucose-6-phosphate isomerase
(G6PI)-induced arthritis. DBA/1 mice were immunized with G6PI + complete Freund’s adjuvant on day 0, after T regulatory cell depletion with
anti-CD25 Ab (days −8 and −11). Treatments were administered starting on day 12 (red dotted line). Samples were obtained on day 36. a Time
course for arthritis scores. b Mean weight of both inguinal lymph nodes. c Mean ankle thickness of both hind paws measured with a manual
caliper. d Histopathological scores for tarsus and pannus formation in both phalanges and tarsus. Representative histological sections of tarsal
joints are also shown (bar 500 μM). e Time course for arthritis scores for mice with mild, moderate and severe arthritis at the time of treatment
initiation. Graphs show mean (± standard error of the mean) for 2–10 mice/group, *p <0.05 versus vehicle control. N naive, Veh vehicle
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Next, we compared the efficacy of dual JAKi + SYKi with
anti-TNF therapy, a standard anti-rheumatic biological
approach used in the clinics. Previous reports showed that
anti-TNF prevents the development of very early acute
G6PI arthritis [20, 26]. Here, we started treatment of
Treg-depleted G6PI immunized mice when arthritic
symptoms were moderate to severe. Interestingly, both
TNF blockade (10 mg/kg, every third day) and dual JAKi
+ SYKi stopped disease worsening but only dual treatment
was able to progressively decrease the clinical score, which
had decreased by over 60 % at the endpoint (Fig. 3a). The
average area under the clinical score curve decreased by
42 % with dual treatment, while it only decreased by 25 %
with etanercept (not shown). Accordingly, lymph node
weight (Fig. 3b) and ankle thickness (Fig. 3c) were signifi-
cantly lower in all mice treated with JAKi + SYKi but not
with anti-TNF. Moreover, 66 % of dual-treated mice expe-
rienced complete recovery of phalangeal joints after
3 weeks of treatment (not shown). Blinded histologic ob-
servations also confirmed reduced recruitment of immune
and inflammatory cells and joint damage in tarsal joints of
mice treated with JAKi + SYKi but not in anti-TNF-
treated mice (Fig. 3d). Abnormal layers of granulation and
fibrovascular tissue (pannus) were abundant in joints of
vehicle-treated mice, which coincides with chronic and
severe stages of arthritis. Dual inhibition significantly
reduced pannus progression in both tarsal and phalangeal
joints, while anti-TNF treatment only had a partial effect
in phalanges. Furthermore, Fig. 3e shows that dual kinase
inhibition reversed the pathological changes in mice with
mild and moderate disease and decreased symptoms in
mice with very severe disease. In contrast, blockade of
TNF stopped, without improving, disease progression in
all groups. Thus, dual JAK + SYK inhibition also presents
greater efficacy than anti-TNF treatment in this experi-
mental model of severe arthritis.
Evaluation of potential immunotoxicity of dual JAK + SYK
inhibition
We next evaluated whether the benefit of greater effi-
cacy of dual JAKi + SYKi in arthritis was limited by in-
creased adverse effects imputable to target inhibition. To
this end, mouse weight as well as hematological and im-
munological parameters were examined in mice immu-
nized either with G6PI + CFA (Figs. 4a-c and 5a) or with
KLH (Fig. 4d-f ) and treated for extended periods of
time, i.e., 3 or 4 weeks, respectively. KLH is an immuno-
gen routinely used in the rodent TDAR model, which al-
lows detection of potential immunotoxicity, especially
immunosuppression. As shown in Additional file 3a and
b, the body weight from mice treated with JAKi/SYKi
remained comparable to vehicle-treated animals. As ex-
pected, the control immunosuppressant drug prednisol-
one significantly reduced body weight, circulating white
blood cells, spleen weight and both CD4+ T cell and B
cell counts in G6PI- and KLH-immunized mice. Kinase
inhibitors alone or in combination and anti-TNF treat-
ment did not alter red blood cell or white blood cell
numbers. Dual JAKi + SYKi and single JAKi decreased
spleen weight compared to G6PI-immunized controls
but never below naive levels, and without affecting CD4
+ T cell and B cell counts. In the TDAR model, dual JAK
+ SYK inhibition, but not etanercept, decreased B cell
counts but never below baseline, and consequently,
KLH-specific antibody production was also only mildly
reduced.
Preclinical studies and clinical trials with tofacitinib
have highlighted an impact on Treg cells. Here, we also
observed a significant decrease in Treg counts in the
spleen of mice treated with tofacitinib and, consequently,
also with dual JAKi + SYKi, but not SYKi alone (Fig. 5a).
Similar diminished Treg numbers were identified in
prednisolone-treated mice.
We also examined potential effects of JAKi, SYKi and
TNF blockade on cytotoxic cell populations (Fig. 5a).
CD8+ T cell counts were similar in all groups. In con-
trast, dual inhibition, but not anti-TNF (not shown)
significantly impacted on natural killer (NK) cell num-
bers, likely due to a direct effect of JAK inhibition on
IL-15 signaling. Under these conditions, we observed a
fully functional cell-mediated cytotoxic response of in
vivo treated splenocytes on target YAC-1 cells upon co-
culture (Fig. 5b left). Comparable results were obtained
in another cytotoxic assay with murine splenocytes
from naive mice but, this time, treated in vitro with
physiologically relevant (0.5 μM), and ten times higher
(5 μM), concentrations (Fig. 5b right). Therefore, re-
duced NK cell numbers upon dual inhibition did not
impact overall cytotoxic activity. In a separate experi-
ment, we confirmed that tofacitinib and PRT062607
were not cytotoxic at the assayed doses (Additional file
3C).
In terms of potential effects on the phagocytic cell
compartment, human PBMCs showed intact phagocyt-
osis of Escherichia coli bioparticles when exposed to
0.5 μM of JAKi and/or SYKi for 1 h (Fig. 5c). At the high
concentration of 5 μM, dual inhibition decreased almost
60 % the phagocytic activity of PBMCs, which can be
explained by the role of SYK on actin cytoskeleton
reorganization during phagocytic vesicle closure. The
flow cytometric analysis revealed CD14+ cells and granu-
locytes to be the main phagocytes involved. Again, these
adverse effects have a limited impact in vivo, as high
plasmatic concentrations are reached only for short
periods of time. Overall, our data show that dual JAK +
SYK inhibition is efficacious and has a good safety pro-
file, and therefore can be seen as a candidate treatment
strategy in arthritis.
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Sustained efficacy and reversed adverse effects after
discontinuation of dual treatment
We next stopped treatment and ten days later 75 % of
arthritic mice treated with both inhibitors either main-
tained or continued to ameliorate clinical signs (Fig. 5d).
In sharp contrast, discontinuation of anti-TNF treatment
led to a worsening of paw inflammation in all mice.
Indeed, an average 17 % increase in the clinical score was
observed in this group, reaching a score comparable to
vehicle-treated arthritic mice. Therefore, the benefits of
dual JAK + SYK inhibition were perpetuated longer than
anti-TNF. Therapy discontinuation also led to immune
recovery. The reduced Treg and NK cell counts after daily
JAKi + SYKi were quickly restored to normal levels
(Fig. 5e), which minimizes potential adverse effects.
Dual JAK + SYK inhibition impacts the development and
function of synoviocytes and osteoclasts
Resident cells of the joint are major contributors to arth-
ritis pathology. In particular, FLS and osteoclasts repre-
sent a link between joint inflammation and structural
damage, which is critical in the functional disability of
RA patients. Here, we studied the importance of the
JAK and SYK pathways on their function in order to
understand the mechanism leading to increased efficacy
of dual JAKi + SYKi. FLS were isolated from small joints
of mice with chronic arthritis (Treg-depleted). Stimula-
tion of FLS with TNF and IL-17A, which are elevated in
arthritic mice (Fig. 1 and Additional file 2) and in the
synovium of RA patients [27, 28], induced IL-6 and
MMP production (Fig. 6a). Dual JAKi + SYKi markedly
Fig. 4 Evaluation of potential immunotoxicity in in vivo assays. a-c DBA/1 mice were immunized with glucose-6-phosphate isomerase (G6PI) + complete
Freund’s adjuvant and exposed to treatment daily for 31 days. a Red blood cell counts and leucocyte counts in peripheral blood. b Splenocyte numbers.
c Numbers of CD4+ T cells (CD3+CD4+CD8−) and B cells (CD3−CD19+MHCII+) in spleens. d-f CD-1 mice were treated from day −14 to 14 and immunized
with keyhole limpet hemocyanin (KLH) on day 0 (T cell-dependent antibody response (TDAR) assay). d Red blood cell counts in peripheral
blood. e Numbers of CD4+ T cells (CD3+CD4+CD8−) and B cells (CD3−CD19+MHCII+) in the spleen. f Levels of KLH-specific IgM and IgGs in plasma at
day 7 and 14, respectively. Graphs show mean (+ standard error of the mean) for 3–6 mice/group, *p <0.05 versus vehicle control, #p <0.05 versus
non-immunized and untreated group (naive). N naive, Veh vehicle, JAKi Janus kinase inhibitor, SYKi spleen tyrosine kinase inhibitor, Pred prednisolone
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reduced IL-6 secretion to a similar extent to JAKi. Milder
effects were observed in MMP9 and MMP3 levels (not
shown). In a transwell system with collagen-coated inserts,
JAKi, SYKi and dual JAKi + SYKi decreased the invasive
capacity of FLS by 13, 27 and 50 %, respectively (Fig. 6b).
Therefore, JAK mediated cytokine production, and both
JAK and SYK additively contributed to collagen invasive-
ness, a critical step in cartilage destruction.
Fig. 5 Evaluation of potential immunotoxicity in in vitro/in vivo assays and effects of treatment withdrawal. a Numbers of T regulatory (Treg) cells (CD3
+CD4+CD25hiFoxp3+), CD8+ T cells (CD3+CD8+CD4−) and natural killer (NK) cells (CD3−CD49bhi) in DBA/1 mice immunized with glucose-6-phosphate
isomerase (G6PI) + complete Freund’s adjuvant and exposed to treatment daily for 31 days. b Cell-mediated cytotoxicity assay with splenocytes either
treated in vivo (left) or in vitro (right) and YAC-1 as target cells. c Phagocytic activity of peripheral blood mononuclear cells (PBMC) treated in vitro. d Time
course for arthritis scores and numbers of Treg cells and NK cells in the spleen of G6PI-immunized mice treated for 35 days and sacrificed on day 47.
Graphs show mean (+ standard error of the mean) for 2–6 mice/group, *p <0.05 versus vehicle or media control, #p <0.05 versus non-immunized and un-
treated group (naive). N naive, Veh vehicle, Predni prednisolone, TC target cells, Med media, JAKi Janus kinase inhibitor, SYKi spleen tyrosine kinase inhibitor
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In bone destruction, osteoclasts are the primary
resorbing cells. Here, we found that G6PI-immunized
mice treated with JAKi + SYKi had baseline counts of
osteoclast precursors (CD11bhiGr1− cells) and levels
of RANKL expression in spleens (Fig. 6c and d). Fur-
thermore, in vitro osteoclastogenesis from bone marrow
cells was completely prevented with SYKi and dual JAKi
+ SYKi exposure (Fig. 6e). We also exposed mature osteo-
clasts to these inhibitors and observed that SYK, but not
JAK, is critically required for bone resorption activity
(Fig. 6f). Thus, dual JAKi + SYKi treatment interferes at
multiple stages in osteoclast development and function,
primarily via SYK.
Dual JAK + SYK inhibition also regulates effector and
memory CD4+T cells and plasma cells
The JAK/STAT pathway is known to mediate T cell differ-
entiation by interfering with cytokine signaling. Our data
show that dual JAKi + SYKi prevented T cell proliferation
upon unspecific stimulation in vitro (Fig. 7a). Antigen-
specific responses, primarily IFNγ and IL-6 production,
were also markedly decreased in splenocytes from arthritic
mice treated in vitro with both inhibitors (Fig. 7b).
Cells of the immunological memory, in particular
memory T cells and long-lived plasma cells are impli-
cated in the chronification of disease and have proven to
be refractory to conventional immunosuppression [29].
In order to investigate the role of JAK and SYK on
memory cell maintenance, OVA-immunized mice were
treated with inhibitors starting 2 weeks after challenge, a
time when memory cells are already generated. The
number of memory CD4+CD44hi T cells was similarly de-
creased in mice treated with JAKi and dual JAKi + SYKi
(Fig. 7c). Upon OVA re-exposure in vitro, JAKi + SYKi
markedly reduced antigen-specific (CD40L+) CD4+ T cells
and their ability to produce IFNγ, IL-2 and TNFα (Fig. 7d
and e). OVA-specific memory plasma cells (CD138+κλhi)
were also significantly reduced by an additive effect on
JAK and SYK signaling (Fig. 7f). Thus, both JAK and SYK
mediate memory cell pool maintenance and, thus, their
Fig. 6 Effects of Janus kinase (JAK) + spleen tyrosine kinase (SYK) inhibition on fibroblast-like synoviocytes and osteoclasts. a Cytokine and matrix
metalloproteinase (MMP) production by fibroblast-like synoviocytes (FLS) from arthritic mice stimulated with 10 ng/ml rmTNF and 50 ng/ml rmIL-17A
and treated in vitro with kinase inhibitors (0.5 μM) for 24 h. b Representative images after crystal violet staining and data showing the invasive potential
of FLS from arthritic mice treated with kinase inhibitors (0.5 μM) in transwell collagen-coated chambers for 48 h. c Numbers of CD11bhiGr1−cells, which
contain most osteoclast precursors, and d rank ligand (RANKL) expression in spleens of DBA/1 mice immunized with glucose-6-phosphate isomerase +
complete Freund’s adjuvant and exposed to JAK inhibitor (JAKi) + SYK inhibitor (SYKi) daily for a month. e Representative images after tartrate-resistant
alkaline phosphatase staining showing the impact of JAKi/SYKi on osteoclast differentiation from bone marrow cells after 5 days in a RANKL +M-CSF
enriched culture. f Activity of mature osteoclasts on cortical bone slices treated with kinase inhibitors (0.5 μM) for 48 h. Graphs show mean (+ standard
error of the mean) of a representative experiment of 2–4 with 3–7 samples/group, *p <0.05 versus dimethyl sulfoxide (DMSO) or naive control. Veh vehicle
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inhibition could maintain disease remission and prevent
arthritis recurrence.
Discussion
Tofacitinib has demonstrated high efficacy in phase II
and III trials and even in patients not responding to
current treatments. However, the response is limited
(ACR20 48–51 %) [12, 13], so there are still difficult-to-
treat patients with RA in need of new therapeutic
approaches. To our knowledge, no clinical trial has eval-
uated the potential benefits of a selective SYK inhibitor
in RA patients. Here, we studied whether the addition of a
SYK inhibitor into a JAK inhibition therapy could improve
the efficacy achieved by single inhibition. We used the
murine Treg-depleted G6PI-induced arthritis model, a
clinically relevant model characterized by non-remitting
and progressive peripheral polyarthritis with loss of joint
structure and function [21].
In a preventive protocol, our data clearly show that
combined JAKi + SYKi offers greater prophylactic effi-
cacy than single kinase inhibition (Fig. 1). Mice treated
with JAKi alone had very mild disease that completely
resolved within 2 weeks. At study termination, there
were no signs of inflammation and joint morphology
looked normal. These results can be in part explained by
the importance of JAK on Th cell differentiation and
function [30], and the critical role of CD4+ T cells in the
induction phase of this chronic G6PI model [21] and
others [31]. Here, we found that antigen-specific T cell
responses were similarly reduced in JAKi- and JAKi +
SYKi-treated mice. Inhibition of JAKs also reduced the
number of activated DCs. Recent reports show that JAK
inhibition profoundly modulates DC development and
Fig. 7 Effects of Janus kinase (JAK) + spleen tyrosine kinase (SYK) inhibition on effector and memory T and B cells. a Proliferation of purified T
cells stimulated with 1 μg/ml anti-CD3 and 0.5 μg/ml anti-CD28 Abs in the presence of kinase inhibitors (0.5 μM) for 72 h. b Cytokine secretion
by splenocytes from arthritic mice in vitro re-exposed to 20 μg/ml recombinant human glucose-6-phosphate isomerase (G6PI) and treated with
JAK inhibitor (JAKi) + SYK inhibitor (SYKi) (0.5 μM) for 72 h. c-f BALB/c mice were immunized and challenged with ovalbumin (OVA) + alum; 2 weeks
after challenge, mice were treated with kinase inhibitors for 11 days. c-e Numbers of memory CD4+ T cells (CD3+CD4+CD44hi), antigen-specific
(CD3+CD4+CD44hiCD40L+) and cytokine-producing (CD40L+cytokine+) memory CD4+ T cells upon OVA re-exposure in vitro. f Numbers of OVA-specific
memory plasma cells (CD138+κλhiOVA+ 5-Bromo-2′-deoxyuridine+). Graphs show mean (+ standard error of the mean) for 3–5 mice/group, *p <0.05
versus media or vehicle control. Med media, Veh vehicle
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activation, which is most likely due to signaling blockade
of the critical differentiating signals GM-CSF and IL-4
[32–34]. In this scenario of reduced DC and T cell
activation, it is not surprising to see lower numbers of
activated B cells and G6PI-specific IgGs upon JAK inhib-
ition. Single inhibition of SYK led to the development of
milder arthritis. A greater role for SYK on disease induc-
tion has been reported in other models; in particular, gen-
etic deficiency of Syk in the hematopoietic compartment
completely blocked the development of arthritis in the K/
BxN serum-transfer murine model [35] and Coffey et al.
[19] reported PRT062607 to dose-dependently reduce the
development of paw inflammation in a murine CAIA
model. While greater doses of SYKi could be administered
to likely enhance efficacy, we did not want to compromise
kinase selectivity. Mice treated with SYKi had decreased
numbers of activated DCs, B cells and IgG levels, likely
explained by the role of SYK on B cell receptor (BCR) sig-
naling and DC maturation via C type lectin receptors [36].
Thus, both JAK and SYK signaling pathways are involved
in early pathogenic mechanisms of arthritis and simultan-
eous inhibition of both kinases results in greater efficacy.
We also followed a curative protocol (Fig. 2), in which
treatment was started at day 12 post-immunization,
when clinical signs were clearly present and affected
multiple joints. Under these conditions, inhibition of
SYK resulted in a minimal (non-significant) decrease of
arthritis parameters. Our results are in contrast with a
previous preclinical study in the rat CIA model showing
significant efficacy of PRT062607 when treatment was
initiated early, i.e., when at least one hind paw showed
first signs of inflammation (score 1) [19]. These differ-
ences in efficacy may result from using distinct experi-
mental models (CIA in rat is acute and less stringent)
and starting treatment at different disease stages (mild
versus moderate). Inhibition of JAK immediately stopped
disease worsening and started to ameliorate clinical signs
after 2 weeks of daily treatment, ending with moderate
disease. These results parallel the responses of arthritic
patients to tofacitinib, i.e., significant clinical and phys-
ical improvement as early as 2 weeks and inhibition of
progress in joint destruction after 6 months of treatment
[9, 12, 14]. This lower efficacy of JAKi in the curative
protocol compared to the preventive one can be partially
explained by the reduced importance of effector CD4+ T
cells when disease is already established. Indeed, Frey et
al. [21] reported that the effector phase of arthritis in the
Treg-depleted G6PI model is non-dependent on CD4+ T
cells, when other cell populations, such as phagocytes, are
more relevant. If multiple local cells of the joint, rather
than adaptive immune cells, drive disease progression dur-
ing the effector phase of arthritis, it is not surprising to
see that therapeutically targeting two signaling pathways is
more effective than targeting only one. Indeed, the
observed changes after dual JAKi + SYKi were impressive,
with no symptoms to minimal symptoms at study termin-
ation. In fact, dual inhibition decreased clinical scores in
all mice with distinct degrees of arthritis severity, showing
87 %, 90 % and 30 % reduction in mild, moderate and
severe arthritis, respectively (Fig. 3d).
To further support this notion of broader amelioration
with multi-pathway inhibition, dual JAKi + SYKi also re-
sulted in higher efficacy than anti-TNF therapy, the most
common first choice biologic strategy (ACR guidelines
2012) (Fig. 3). Blockade of TNF with etanercept stopped,
without improving, disease progression in mice with
mild, moderate and severe arthritis, resulting in an aver-
age clinical score 25 % lower than vehicle-treated mice,
but 39 % higher than dual treatment. Furthermore, par-
tial arthritis amelioration after etanercept treatment was
only observed in phalangeal joints, as tarsus remained
with maximal inflammatory infiltrates, pannus and
severe bone/cartilage erosion. To confirm the activity of
the drug used, we found that etanercept was able to pre-
vent disease onset in CIA mice (not shown). Thus, tar-
geting only one pro-inflammatory signal when severe
and erosive disease is already established results in
reduced and slower recovery than dual JAKi + SYKi
treatment. The observed partial efficacy of TNF block-
ade under these severe conditions is not surprising, as
30–40 % of RA patients have an inadequate response to
TNF inhibitors [37–39]. The increased efficacy of our
proposed mechanism of action in this demanding model
of arthritis, in which other therapies fail, suggests JAKi
+ SYKi as a potential pharmacological tool to treat
patients not responding to current treatments. Our data
also endorse the use of the chronic G6PI model to inves-
tigate difficult-to-treat arthritis.
The benefits of dual JAKi + SYKi need to be consid-
ered in the context of the risks of adverse events. The
most common target-related adverse effects observed in
clinical trials with JAK include a higher incidence of in-
fection (resulting from immunosuppression) and anemia
[14]. Of note, companies have minimized or overcome
some adverse events by optimizing the dose and posol-
ogy. Our data revealed that a month of daily treatment
with JAKi + SYKi did not reduce total circulating leuco-
cytes or red blood cell counts, hemoglobin or hematocrit
levels in arthritic (Fig. 4) and healthy KLH-immunized
mice (not shown). The weight and cellularity (not
shown) of spleens and lymph nodes were decreased but
never below those from naive mice or those treated with
prednisolone, a well-known immunosuppressive agent.
A phenotypic analysis in the spleen revealed no signifi-
cant changes on CD4+ T or B cell counts in all treated
arthritic mice, albeit B cells were reduced to baseline
numbers in KLH-immunized mice. Such reduction was
paralleled by lower KLH-specific IgG production, which
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is consistent with the observed reduction in the levels of
G6PI-specific IgG (Fig. 1). Importantly for host defense
against pathogens, the ability to generate antibodies was
never completely abolished by single or dual treatment,
allowing these treated mice to still mount robust
antigen-specific humoral responses. A study in monkeys
also reported none to modest effects on leucocytes, T
and B cell counts after chronic (3-week), oral tofacitinib
administration [40]. In contrast, mice deficient on JAK3
(JAK3−/−), common γc (γc−/−) or receiving tofacitinib by
infusion with osmotic minipumps showed marked re-
ductions in T and B cell numbers [41–44]. These suggest
that intermittent, rather than continuous, kinase inhib-
ition reduces immunosuppression without compromis-
ing efficacy.
Non-specific defense mechanisms, including cytotox-
icity and phagocytosis, were also preserved in mice
exposed to physiologically relevant concentrations of
JAKi + SYKi (Fig. 5). Numbers of CD8+ T cells and neu-
trophils (not shown) were comparable among healthy
and treated mice. In contrast, NK cell counts signifi-
cantly decreased 43 % and 53 % after chronic JAKi or
JAKi + SYKi, respectively. This selective effect on NK
cells was already observed after 6 days of treatment (not
shown) and is in accordance with the reported time- and
dose-dependent reduction of circulating NK cells after
tofacitinib administration [40]. JAK3−/− and γc−/− mice
also exhibited a profound loss of NK cells [44], which is
consistent with the known role of IL-15 and IL-21 for
their homeostasis [45]. Importantly, a reduction only in
this population was not sufficient to impact overall cyto-
toxicity. After chronic treatment with dual JAKi + SYKi,
the number of CD3+CD4+CD25brightFoxp3+ T cells
(Treg) decreased 70 % from baseline. A comparable de-
crease was observed in mice treated with JAKi, which
could be explained by the critical requirement of IL-2/
JAK1&3/STAT5 signaling for the maturation of FOXP3+
Tregs [46, 47]. Decreased Treg counts after chronic tofa-
citinib administration has been reported by others that
further demonstrate that the regulatory capacities of the
residual Treg cells remain normal [48]. Collectively, our
data show that the potential target-related adverse
effects of dual inhibition do not increase compared to
each single inhibition and are mitigated because we man-
aged to transiently inhibit JAK and SYK signaling. In
particular, 6–12 h compound coverage (Additional file 1)
was sufficient to ameliorate the disease in this model and
allow enough time for most basic physiological processes
to recover homeostasis.
It is important for safety and economic reasons to
consider the possibility of therapy withdrawal. Here we
show that the significant reduction in Treg and NK cell
counts in mice chronically exposed to JAKi + SYKi was
quickly reversed after treatment discontinuation (Fig. 5).
Interestingly, the clinical score of these mice remained
low, suggesting long-lasting effects of dual treatment. In
sharp contrast, discontinuation of anti-TNF treatment
led to a prompt rebound of disease, i.e., clinical scores
reached arthritic control severity in less than a week.
Thus, the specific immune suppression resulting from
dual JAKi + SYKi treatment can be easily reversed with-
out compromising efficacy. Further studies should deter-
mine the optimal treatment regimen to preserve the
clinical benefit, avoid disease recurrence and reduce
adverse events.
In order to understand the mechanism leading to
increased efficacy by dual JAKi + SYKi, we studied the
contribution of these kinase pathways on specific cell
subsets relevant to disease pathology (Figs. 6 and 7).
Local FLS and osteoclasts are major effectors of joint in-
flammation (synovitis) and destruction, and therefore
are important therapeutic targets in RA. Our data show
that JAKi + SYKi significantly reduced the aggressive
phenotype of arthritic FLS (Fig. 6a and b). Interestingly,
cytokine production upon TNF + IL-17A stimulation
was primarily JAK-dependent, while SYK signaling
contributed more to FLS invasiveness. In this regard, the
JAK-STAT pathway has been implicated in TNF and IL-
17 signaling via autocrine production of IFNβ and PI3K
activation, respectively [49–51]; and SYK is involved in
the signaling of integrins that mediate FLS adhesion and
invasion to the extracellular matrix, an important initiat-
ing step in the progressive destruction of articular cartil-
age (reviewed in [52, 53]). Dual JAKi + SYKi also
prevented extensive bone destruction by altering both
osteoclastogenesis and osteoclast activity (Fig. 6c-f). In
particular, we found that mice treated with JAKi + SYKi
had fewer CD11bhiGr1-/lo splenocytes, a population with
osteoclast-forming potential; in fact, 60–70 % of these
cells are known to differentiate into TRAP+ osteoclasts
when cultured with RANKL and M-CSF [54, 55]. Dual
JAKi + SYKi, solely via SYKi, completely blocked inter-
cellular fusion and bone erosion activity but osteoclasts
still showed partial TRAP activity (not shown). This is in
accordance with syk−/− osteoclasts, which do not differ-
entiate morphologically but still express mature osteo-
clast markers, and also show impaired functional
resorption of mineralized matrix [18]. These alterations
are likely explained by the importance of SYK on cyto-
skeletal rearrangements and specific integrin-mediated
functions (reviewed in [56, 57]. These in vitro results
along with our histopathological data from arthritic mice
(Fig. 2g) reinforce the idea that affecting multiple cell
types with dual inhibition is more effective than single
inhibition in this complex system.
There are a growing number of reports pointing to the
importance of chronically activated synovial T cells for the
stimulation of resident FLS and osteoclast precursors. Our
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data show that dual JAKi + SYKi markedly reduced T cell
proliferation and cytokine production upon unspecific
stimulation or antigen re-exposure, suggesting a counter-
acting effect on aberrant T cell activity (Fig. 7). It is likely
that this effect was IL-2 driven, and, thus, more dependent
on JAK. RANKL expression, primarily found on T cells
but also B cells and FLS [58, 59], was also significantly
lower in JAKi + SYKi-treated mice, which further contrib-
utes to decreasing osteoclast differentiation and activity.
T and B cells have been suggested to also play a key
role in the perpetuation and recurrence of symptoms,
in part due to the generation of immunological mem-
ory. Therefore, combating autoimmune memory, yet a
challenge, is seen as an important clinical goal. Here,
our data show that the memory CD4+ T cell pool and,
to a greater extent, the antigen-specific effector subset
were significantly reduced after JAKi + SYKi treatment.
As treatment was started 2 weeks after antigen chal-
lenge, a time when memory cells are already generated
[60, 61], our data suggest an effect of JAKi on memory
T cell maintenance. In this regard, IL-7 is known to be
critical for memory CD4 cell survival [62], and IL-7 sig-
nals via the JAK1/JAK3-STAT5 pathway. Dual treat-
ment also reduced the number of antigen-specific
memory plasma cells (CD138+κλhi). While the factors
involved in plasma cell survival are poorly understood,
we speculate that blockade of IL-6 signaling via the
JAK1-STAT3 pathway, and perhaps B cell activating
factor (BAFF) responsiveness, which has recently been
shown to require SYK, may explain the reduced mem-
ory plasma cell counts [63, 64].
RA initiates many years before clinical onset, which
raises the demands for prevention and early diagnosis.
Our data suggest simultaneous inhibition of JAK + SYK
to be a very efficacious treatment strategy at early stages
of disease development, as it interferes with multiple
steps of the immunization process, i.e., activation of
DCs, B cells and T cells. Our work also shows that dual
inhibition is more effective than current therapeutic
strategies, namely anti-TNF or single JAKi, in ameliorat-
ing severe disease manifestations. Paw inflammation,
bone erosion and cartilage damage were significantly re-
duced in mice treated with JAKi + SYKi, as a result of
interfering in systemic T/B cell functions and in local
destructive events, primarily osteoclast and FLS activity.
Thus, efficacy resulted from interfering with the activity
of multiple cells, and perhaps reducing compensatory
disease mechanisms. Importantly, intermittent suppres-
sion of individual targets was sufficient to modulate dis-
ease activity and reduce adverse events. Overall, the
greater and broader anti-rheumatic action of adding
SYK inhibition to a JAK inhibition therapy hold experi-
mental promise but will need confirmation from clinical
studies.
Conclusions
The present study collectively suggests that dual JAK +
SYK inhibition with selective, potent and orally bioavail-
able small molecules could complement the current
arsenal of tools in development for the treatment of
rheumatoid arthritis and likely other inflammatory and
autoimmune disorders.
Additional files
Additional file 1: Potency, selectivity and pharmacokinetics of
tofacitinib/CP-690,550 (Janus kinase inhibitor (JAKi)) and PRT-062607
(spleen tyrosine kinase inhibitor (SYKi)). a, b Human cell lines were
pre-incubated with increasing concentrations of JAKi or SYKi (0.005 to 5 μM)
for 1 h and then stimulated with either 100 ng/ml rmIL-6 for 15 minutes or
10 μg/ml anti-IgM for 5 minutes. Cells were fixed, permeabilized, stained
with anti-STAT3(pY705)-Alexa Fluor 647 or anti-BLNK(pY84)-Alexa Fluor 488
and quantified by flow cytometry. Half maximal inhibitory concentration
(IC50) was extrapolated from an inhibition vs log (concentration) curve. c
Collagen-induced arthritis (CIA) model. DBA/1 mice were immunized on day
0 with type II collagen (100 μg/mouse, subcutaneous administration (s.c.))
emulsified in complete Freund’s adjuvant (CFA) and boosted on day 21.
Starting on day 30, when disease was mild, mice were orally treated once a
day with increasing doses of JAKi (3.75 to 30 mg/kg). Graph shows mean for
6–8 mice/group. d Collagen antibody-induced arthritis (CAIA) model. BALB/c
mice received a cocktail of monoclonal antibodies (2 mg, intravenous
administration (i.v.)) directed against type II collagen on day 0 and a
lipolysaccharide challenge (70 μg, intraperitoneal administration (i.p.))
on day 3. Twice daily treatment with 30 mg/kg SYKi started on day
4. Graph shows mean for 6–8 mice/group. For monitoring both CIA
and CAIA models, each paw was scored individually on a scale of 0–4, with
4 indicating the most severe swelling and erythema. e DBA/1 mice received
a single oral dose of JAKi (20 mg/kg) or SYKi (30 mg/kg) and plasmatic drug
concentration was determined by liquid chromatography-tandem
mass spectrometry. Graph shows mean for 2–7 mice/group and a
line representing IC50 values obtained in a and b. (PDF 755 kb)
Additional file 2: Clinical and immunological comparison of acute
versus chronic glucose-6-phosphate isomerase (G6PI)-induced arthritis
model in mice. a Diagram summarizing the experimental protocol followed
in Figs. 1, 2, 3, 4 and 5 (see “Methods” for more details). b Time course for
arthritis scores clearly showing moderate and acute arthritis in
G6PI-immunized mice, and severe and chronic arthritis in T regulatory cell
(Treg)-depleted and G6PI-immunized mice. c Proportion of CD25hiFoxp3+
Treg cells in CD3+CD4+ cells at the time of immunization (day 0). d
Numbers of total cells from inguinal lymph nodes and e leucocyte counts in
peripheral blood at day 6 post-immunization. f Cytokine secretion by
splenocytes isolated on day 31 and stimulated in vitro with 20 μg/ml G6PI for
72 h. Graphs show mean (± standard error of the mean) for 3–6 mice/group,
*p <0.05 versus naive control, #p <0.05 versus G6PI-immunized mice. s.c.
subcutaneous administration, i.v. intravenous administration, i.p. intraperitoneal
administration, p.o. oral administration, QD one dose a day. (PDF 521 kb)
Additional file 3: Effect of Janus kinase inhibitor (JAKi)/spleen tyrosine
kinase inhibitor (SYKi) treatment on body weight and cell viability. a
DBA/1 mice were immunized with glucose-6-phosphate isomerase (G6PI) +
complete Freund’s adjuvant (CFA) on day 0. b CD-1 mice were immunized
with keyhole limpet hemocyanin (KLH) on day 14 (T cell-dependent antibody
response (TDAR) assay). a, b Relative body weight to day 0 (before treatment
started) was recorded regularly. As expected, naive animals progressively
gained weight over time and treatment with the glucocorticoid prednisone
induced the most significant decrease in body weight. G6PI immunization
triggered the development of arthritis and, therefore, vehicle-treated animals
initially lost weight and then slowly recovered. Modest changes were
observed in vehicle-exposed mice upon KLH immunization. Body weight in
mice daily treated with single or dual JAK/SYK inhibition was comparable to,
or even better than, vehicle-treated animals, clearly showing that treatment
with JAKi + SYKi did not negatively impact the general wellbeing of mice.
c HepG2 cells were exposed for 72 h to increasing doses of JAKi/SYKi (0.5, 5
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or 50 μM) or diclofenac (positive control of hepatotoxicity) and mitochondrial
activity was evaluated by Alamar Blue fluorescence. JAKi did not show any
cytotoxic effect at the assayed concentrations. SYKi significantly decreased cell
viability only at the highest dose (50 μM). Importantly, plasma levels of SYKi
peaked at 3–4 μM and for a very short time (see Additional file 1e); therefore,
higher and sustained concentrations are never reached in vivo. These data
show that combined inhibition of JAK + SYK does not result in higher general
toxicity. Graphs show mean (± standard error of the mean) for 3–6 mice/
group or 2–10 replicates/condition, *p <0.05 versus media (untreated cells).
Med media, Diclo diclofenac, Predni prednisolone. (PDF 432 kb)
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